Current clinical guidelines for NSCLC recommend a comprehensive molecular profiling encompasses 11 driver genes, including EGFR mutations, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, MET ex14 skipping, RET, and ERBB2 (HER2). Here, ALK is linked to non-small cell lung carcinoma.